Fig. 4 |. Overall survival and quality of life deterioration across positive first-line trials involving patients with advanced-stage hepatocellular carcinoma.
Forest plots summarizing hazard ratios (HR) and 95% confidence intervals (CI) for (part a) overall survival (OS) and (part b) time to deterioration of global health status and quality of life (GHS/QOL) according to the European Organisation for Research and Treatment of Cancer quality of life questionnaire C30 across pivotal positive first-line trials involving patients with advanced-stage hepatocellular carcinoma. In part a, all treatments are compared with sorafenib, except for the SHARP trial in which the control group received placebo. In part b, QOL among patients receiving active treatment is compared with sorafenib. The horizontal lines indicate hazard ratios and ranges (teal, studies demonstrating superiority; dark yellow, studies demonstrating non-inferiority). The vertical dashed lines represent hazard ratios of 1.0 (reference) and 1.08 (non-inferiority margin). STRIDE, single tremelimumab regular interval durvalumab.